<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02979119</url>
  </required_header>
  <id_info>
    <org_study_id>Version 5.1 June 2014</org_study_id>
    <nct_id>NCT02979119</nct_id>
  </id_info>
  <brief_title>The European Paediatric Network for Haemophilia Management ( PedNet Registry)</brief_title>
  <acronym>PedNet</acronym>
  <official_title>The European Paediatric Network for Haemophilia Management and the PedNet Haemophilia Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PedNet Haemophilia Research Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Lund University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>PedNet Haemophilia Research Foundation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale:

      Haemophilia is a rare disease; to improve knowledge international collaboration is needed.
      Well-defined clinical data will be collected from complete cohorts in order to prevent
      selection bias.

      Objective:

      To collect data on bleeding during neonatal period, endogenous (genetic) and exogenous
      (treatment-related) determinants of inhibitor development and long term outcome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Design: Prospective observational cohort

      Population:

      Patients with haemophilia A and B with FVIII/IX levels of &lt;1 to 25% born between 1-1-2000 and
      1-1-2020.

      Intervention:

      No intervention; only documentation of patient characteristics and parameters of routine
      patient care and outcome

      Main outcome parameters:

      Outcome: clinically relevant inhibitor development, bleeding pattern and joint status on
      physical examination and imaging.

      Determinants: baseline FVIII/IX levels, measurement of inhibitory antibodies, family history,
      FVIII/IX gene mutation, details on replacement therapy (according to each infusion for the
      first 50 treatment days, and annually thereafter) and surgeries.

      Nature and extent of the burden and risks associated with participation, benefit and group
      relatedness:

        -  No burden for the patients. Well-defined clinical data will be collected from the
           medical files. Participating in this registry will not change the number of visits to
           the clinic. All outcome parameters that are collected (including laboratory results) are
           part of routine clinical care.

        -  Direct benefit is not to be expected. However, the direct interaction between centres
           that treat patients with rare diseases improves both clinical care and will result in
           better guidelines and as such may provide indirect benefit.

        -  Multicentre participation: haemophilia is a very rare condition. Therefore, collecting
           data on a multi-centre observational cohort is the only way to study this specific
           population.

        -  The registry concerns young boys with haemophilia and cannot be performed in older
           patients, as &gt;90% of inhibitors occur develop during the first 50 exposure days, and the
           results of prophylactic replacement therapy are highly dependent on the initiation of
           this treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>20 Years</target_duration>
  <primary_outcome>
    <measure>Number of patients with antibody development to exogenous clotting factors</measure>
    <time_frame>Until patient reaches age of 18</time_frame>
    <description>Allo-antibodies against Fact VIII and IX; Blood test: measurement in Bethesda units (BU), positive according to local standards, for most labs &gt;0.5 BU</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Long term outcome of haemophilia on joint status using the Hemophilia Joint Health Score (HJHS) and MRI techniques.</measure>
    <time_frame>From diagnose every 5 years until patient reaches age of 18</time_frame>
    <description>Effect of different prophylactic regimen on bleedings and joint damage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long term outcome different Immune Tolerance Induction (ITI) therapies in patients with inhibitor.</measure>
    <time_frame>From date first positive inhibitor titer every 3 years until patient reaches age of 18</time_frame>
    <description>Effect of different ITI therapies on bleeding and joint damage. Joint damage is assessed using the HJHS and MRI.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">2200</enrollment>
  <condition>Factor VIII Deficiency</condition>
  <condition>Factor IX Deficiency</condition>
  <arm_group>
    <arm_group_label>Prospective Birth cohort</arm_group_label>
    <description>Children with mild ( FVIII/IX 6 to 25%), moderate (FVIII/IX 1 to 5%) or severe (FVIII/IX &lt;1%) haemophilia A or B, born from January 1st 2000 until January 1st 2020 who have been or are to be treated with coagulation proteins in one of the participating centres</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Coagulation proteins</intervention_name>
    <description>Documentation of factor VIII and factor IX products from the first exposure day onwards</description>
    <arm_group_label>Prospective Birth cohort</arm_group_label>
    <other_name>Factor VIII, Factor IX</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Children with mild ( FVIII/IX 6 to 25%), moderate (FVIII/IX 1 to 5%) or severe (FVIII/IX
        &lt;1%) haemophilia A or B, born from January 1st 2000 until January 1st 2020 who have been or
        are to be treated in one of the participating centres
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with Haemophilia A or B

          -  Factor VIII/ IX activity of &lt;1 to 25%

          -  Complete records of Factor treatment and bleeds

          -  Treated in one of the participating centres

        Exclusion Criteria:

          -  Patients referred because of an inhibitor*

          -  Informed consent not obtained
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rolf Ljung, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lund University Hospital, Malmo, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>H. Marijke Van den Berg, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>University Medical Center Utrecht, The Netherlands</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>H. Marijke van den Berg, MD, PhD</last_name>
    <phone>+31850299993</phone>
    <email>h.marijke.vandenberg@pednet.eu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ella van Hardeveld, MANP</last_name>
    <phone>+31850299993</phone>
    <email>e.m.vanhardeveld@pednet.eu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitäts-Klinik für Kinder- und Jugendheilkunde</name>
      <address>
        <city>Graz</city>
        <zip>A-8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Medical University of Vienna - Department of Paediatrics</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph Male, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service of Pediatric Haematology University Hospital Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>B-3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christel Van Geet, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Division of Hematology/Oncology Hôpital St Justine</name>
      <address>
        <city>Montréal</city>
        <zip>H3T 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Rivard, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Division of Haematology/Oncology Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <zip>M5G-1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuel Carcao, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Pediatrics Århus Kommunehospital Skejby Sygehus</name>
      <address>
        <city>Aarhus</city>
        <zip>DK-8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Niels Clausen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Helsinki University Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>FIN-00029</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Mäkipernaa, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service Hématologique Centre Regional Traitement d'Hemophilie Bicetre</name>
      <address>
        <city>Le Kremlin Bicêtre</city>
        <zip>F-94270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Rafowicz, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service d'Hématologie Pédiatrique Hôpital Universitaire La Timone</name>
      <address>
        <city>Marseille Cedex-05</city>
        <zip>F-13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hervé Chambost, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre de traitement des hémophiles Hôpital Universitaire Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>F-31052</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ségolène Claeyssens, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut für Experimentelle Hämatologie und Transfusionsmedizin Universitätsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>D-53127</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johannes Oldenburg, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinik Bremen-Mitte Prof.-Hess-Kinderklinik</name>
      <address>
        <city>Bremen</city>
        <zip>D 28177</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martina Bührlen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Frankfurt &amp; Goethe University - Clinical and Molecular Hemostasis, Department of Pediatrics</name>
      <address>
        <city>Frankfurt am Main</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph Königs, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dr. v. Haunersches Kinderspital University of Munich</name>
      <address>
        <city>Munich</city>
        <zip>D-80337</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karin Kurnik, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hämophilie Zentrum Rhein Main</name>
      <address>
        <city>Mörfelden-Walldorf</city>
        <zip>D-64546</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmen Escuriola, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Haemophilia-Haemostasis Unit St. Sophia Children's Hospital</name>
      <address>
        <city>Athens</city>
        <zip>GR-11527</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helen Platokouki, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept of Paediatric Haematology Our Lady's Children's Hospital for Sick Children Crumlin</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beatrice Nolan, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The National Hemophilia Center Sheba Medical Center, Tel Hashomer</name>
      <address>
        <city>Ramat Gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gili Kenet, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gaslini Hospital</name>
      <address>
        <city>Genova</city>
        <zip>I-16184</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angelo Claudio Molinari, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>A. Bianchi Bonomi Hemophilia and Thrombosis Centre IRCCS Ca' Granda Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Santagostino, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Van Creveld Kliniek University Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3508 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathelijn Fischer, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Heidi Glosli, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Maria - Serviço de Imuno-hemoterapia</name>
      <address>
        <city>Lisbon</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cristina Oliveira, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar São João, S. Imuno-hemoterapia</name>
      <address>
        <city>Porto</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuela Carvalho, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Unitat Hemofilia Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmen Altisent Roca, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Unidad de Coagulopatías Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Theresa Alvarez Roman, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General Unidad de Hemofilia 1 Sur Hospitales Universitarios Virgen del Rocio</name>
      <address>
        <city>Seville</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Unidad de Coagulopatias Congenitas Hospital Universitario la Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Rosa Cid, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lund University Hospital</name>
      <address>
        <city>Malmo</city>
        <zip>S-20502</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rolf Ljung, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Pediatrics, Clinic of Coag. Disorders Karolinska Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>S-17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susanna Ranta, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hämophiliezentrum</name>
      <address>
        <city>Wabern</city>
        <zip>CH_3084</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rainer Kobelt, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Birmingham Children's Hospital NHS Trust - Department of Haematology</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mike Williams, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Hospital for Sick Children</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH9 1LF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Thomas, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Haematology Royal Hospital for Sick Children</name>
      <address>
        <city>Glasgow</city>
        <zip>G 3885</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Chalmers, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Haemophila Center Great Ormond Street Hospital for Children</name>
      <address>
        <city>London</city>
        <zip>WC1N3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ri Liesner, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.pednet.eu</url>
    <description>Website of the PedNet Registry</description>
  </link>
  <results_reference>
    <citation>van den Berg HM, Gouw SC, van der Bom JG. Factor VIII products and inhibitors in severe hemophilia A. N Engl J Med. 2013 Apr 11;368(15):1457. doi: 10.1056/NEJMc1301995.</citation>
    <PMID>23574131</PMID>
  </results_reference>
  <results_reference>
    <citation>Gouw SC, van den Berg HM, Fischer K, Auerswald G, Carcao M, Chalmers E, Chambost H, Kurnik K, Liesner R, Petrini P, Platokouki H, Altisent C, Oldenburg J, Nolan B, Garrido RP, Mancuso ME, Rafowicz A, Williams M, Clausen N, Middelburg RA, Ljung R, van der Bom JG; PedNet and Research of Determinants of INhibitor development (RODIN) Study Group. Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. Blood. 2013 May 16;121(20):4046-55. doi: 10.1182/blood-2012-09-457036. Epub 2013 Apr 3.</citation>
    <PMID>23553768</PMID>
  </results_reference>
  <results_reference>
    <citation>Carcao MD, van den Berg HM, Ljung R, Mancuso ME; PedNet and the Rodin Study Group. Correlation between phenotype and genotype in a large unselected cohort of children with severe hemophilia A. Blood. 2013 May 9;121(19):3946-52, S1. doi: 10.1182/blood-2012-11-469403. Epub 2013 Mar 12.</citation>
    <PMID>23482934</PMID>
  </results_reference>
  <results_reference>
    <citation>Clausen N, Petrini P, Claeyssens-Donadel S, Gouw SC, Liesner R; PedNet and Research of Determinants of Inhibitor development (RODIN) Study Group. Similar bleeding phenotype in young children with haemophilia A or B: a cohort study. Haemophilia. 2014 Nov;20(6):747-55. doi: 10.1111/hae.12470. Epub 2014 Jun 3.</citation>
    <PMID>24893572</PMID>
  </results_reference>
  <results_reference>
    <citation>Fischer K, Ljung R, Platokouki H, Liesner R, Claeyssens S, Smink E, van den Berg HM. Prospective observational cohort studies for studying rare diseases: the European PedNet Haemophilia Registry. Haemophilia. 2014 Jul;20(4):e280-6. doi: 10.1111/hae.12448. Epub 2014 May 2.</citation>
    <PMID>24784937</PMID>
  </results_reference>
  <results_reference>
    <citation>Gouw SC, van der Bom JG, Ljung R, Escuriola C, Cid AR, Claeyssens-Donadel S, van Geet C, Kenet G, Mäkipernaa A, Molinari AC, Muntean W, Kobelt R, Rivard G, Santagostino E, Thomas A, van den Berg HM; PedNet and RODIN Study Group. Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med. 2013 Jan 17;368(3):231-9. doi: 10.1056/NEJMoa1208024.</citation>
    <PMID>23323899</PMID>
  </results_reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2014</study_first_submitted>
  <study_first_submitted_qc>November 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2016</study_first_posted>
  <last_update_submitted>November 3, 2017</last_update_submitted>
  <last_update_submitted_qc>November 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>PedNet Haemophilia Research Foundation</investigator_affiliation>
    <investigator_full_name>Marijke van den Berg</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <keyword>Hemophilia</keyword>
  <keyword>Children, ,</keyword>
  <keyword>Inhibitors,</keyword>
  <keyword>Prophylaxis</keyword>
  <keyword>Long-term outcome</keyword>
  <keyword>Congenital</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
    <mesh_term>Hemophilia B</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Factor VIII</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

